financetom
Business
financetom
/
Business
/
Chewy Seen Beating Q2 EBIDTA Estimate, Raising FY Guidance, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chewy Seen Beating Q2 EBIDTA Estimate, Raising FY Guidance, Morgan Stanley Says
Aug 26, 2024 4:01 PM

02:09 PM EDT, 08/26/2024 (MT Newswires) -- Chewy (CHWY) probably will top EBITDA estimates for fiscal Q2 and boost full-year guidance, partly on "fundamental levers which should drive incremental margin expansion through the year," Morgan Stanley said Monday in a report.

EBIDTA at $123 million in Q2 will top Wall Street's estimate by 8%, Morgan Stanely forecast. The firm expects a "slight beat" on revenue. Results are expected Wednesday.

Chewy has a "durable margin expansion story and the potential for revenue acceleration to the mid to high single digits range as the pet macro normalizes," the report said.

"Pet ownership appears to be stable" from the previous quarter "but not yet inflecting as we continue to expect net adds to return positive" in Q3, the report said.

The firm boosted forecasts for fiscal 2024 EBITDA by 3% and by 2% for fiscal 2025.

Morgan Stanley raised its price target on Chewy stock to $30 from $28 and maintained its overweight.

The company's shares fell 4.6% in recent trading Monday.

Price: 25.48, Change: -1.22, Percent Change: -4.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Begins Phase 3 Trial of Felzartamab for Rare Kidney Disease
Biogen Begins Phase 3 Trial of Felzartamab for Rare Kidney Disease
Jun 30, 2025
08:03 AM EDT, 06/30/2025 (MT Newswires) -- Biogen (BIIB) said Monday it initiated dosing in its global phase 3 trial to evaluate the investigational drug, felzartamab, in adults with primary membranous nephropathy, a severe autoimmune kidney disorder with no approved treatments. The company said the study will compare felzartamab to tacrolimus and enroll around 180 patients, with results expected in...
V2X Awarded 5-Year, $118 Million Contract to Support Iraqi F-16 Program
V2X Awarded 5-Year, $118 Million Contract to Support Iraqi F-16 Program
Jun 30, 2025
08:02 AM EDT, 06/30/2025 (MT Newswires) -- V2X (VVX) said Monday that it has been awarded a new five-year cost-plus-fixed-fee contract worth $118 million to provide support services for Iraq's F-16 fighter jet program. The contract, awarded under the US foreign military sales program, also includes base operations and life support services at Iraq's Martyr Brigadier General Ali Flaih Air...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Tesla Says First Autonomous Vehicle Delivery in US Completed
Tesla Says First Autonomous Vehicle Delivery in US Completed
Jun 30, 2025
08:01 AM EDT, 06/30/2025 (MT Newswires) -- Tesla (TSLA) has completed the first autonomous vehicle delivery in the US, according to separate Saturday posts on the social media platform X by the company and its Chief Executive Elon Musk. In its post, Tesla said a Tesla Model Y vehicle drove itself for 30 minutes from the company's Gigafactory in Texas...
Copyright 2023-2026 - www.financetom.com All Rights Reserved